Forte Biosciences (NASDAQ:FBRX) versus Abivax (NASDAQ:ABVX) Critical Analysis

Forte Biosciences (NASDAQ:FBRX) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings & Valuation

This table compares Forte Biosciences and Abivax”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38 million	($4.64)	-3.99
Abivax	N/A	N/A	-$380.27 million	($5.21)	-17.81

Abivax is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Forte Biosciences has a beta of 2.87, indicating that its stock price is 187% more volatile than the S&P 500. Comparatively, Abivax has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Profitability

This table compares Forte Biosciences and Abivax’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
Abivax	N/A	-99.02%	-70.26%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Forte Biosciences and Abivax, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1	0	3	0	2.50
Abivax	1	2	12	0	2.73

Forte Biosciences presently has a consensus price target of $67.00, indicating a potential upside of 262.06%. Abivax has a consensus price target of $130.08, indicating a potential upside of 40.19%. Given Forte Biosciences’ higher possible upside, equities analysts clearly believe Forte Biosciences is more favorable than Abivax.

Insider & Institutional Ownership

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Forte Biosciences beats Abivax on 7 of the 11 factors compared between the two stocks.

About Forte Biosciences

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

About Abivax

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.